vimarsana.com

Page 3 - மைக்கேல் ஸ்மித் அடித்தளம் க்கு ஆரோக்கியம் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First dose of vaccine in long-term care residents, staff 80% effective: BCCDC

Call for Proposals for COVID-19 Child, Youth & Family Mental Health Impact Grant

Call for Proposals for COVID-19 Child, Youth & Family Mental Health Impact Grant 195SHARES Mental Health Research Canada (MHRC), the Michael Smith Foundation for Health Research (MSFHR) and the BC Ministry of Children and Family Development (MCFD) are partnering to offer a grant of $50,000 to advance understanding of: The impact of COVID-19 on the mental health of families and caregivers who have children and youth with special needs in British Columbia; and The identification of existing evidence-based and promising approaches to mitigating these impacts. All Canadians have been affected in some degree by anxiety, depression and social isolation during this global crisis, but Canadians with more acute needs struggle even more because they can’t engage mental health services with the same frequency.

SARS research receives three-pronged funding and organizational boost - Lab Canada

Ottawa, ON June 11, 2003 The Canadian Institutes of Health Research (CIHR) has unveiled a three-part health research strategy on severe acute respiratory syndrome (SARS). The strategy includes funding of C$1.7 million to four research teams, funding of about $1 million to support related public-health research, and the creation of a research consortium to coordinate, promote and support Canadian research in the area. Leaders of the four teams funded to a total of $1.7 million are: – Dr Mark Loeb (McMaster University), whose team will work to improve our understanding of the diagnosis, clinical course, epidemiology and immunopathogenesis of SARS; – Dr Danuta Skowronski (University of British Columbia), whose team will carry out research leading to the development of a vaccine for SARS;

New interactive maps show community degrees of COVID-19 risk

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.